Implant Sciences Corp Awarded $500,000 Contract Extension from Department of Homeland Security
Implant Sciences zu myNews hinzufügen Was ist das?
Implant Sciences Corporation (AMEX: IMX), a high technology
supplier of sophisticated systems and sensors for the homeland security
market and related industries, today announced $500,000 in follow on
funding from the U.S. Department of Homeland Security ("DHS”),
Science & Technology ("S&T”)
Directorate in Washington, DC for a Counter-Improvised Explosive Device
Program. This award represents further support of a contract awarded to
Ion Metrics, the San Diego based company acquired by the Company in
April 2008. The addition of this $500,000 brings the total contract
value to approximately $2,707,000.
The focus of this contract is to develop integrated, miniaturized
sub-systems for use in the detection and identification of trace
explosives. Implant Sciences’ new San
Diego-based Advanced Technology Group has been actively working on the
development of a hyphenated system incorporating a Quadrupole Array Mass
Spectrometer (QAMS), a miniature Ion Mobility Spectrometer (IMS) and a
Differential Mass Spectrometer (DMS), which would represent a new and
novel technological capability for the Company and the security industry.
"The Counter-Improvised Explosive Device
Program was created in support of efforts by the Science and Technology
Directorate within the Department of Homeland Security to leverage
existing resources into new and more effective products to help further
protect our country,” stated Phillip C.
Thomas, President and CEO of Implant Sciences. "Along
with partners at the University of Florida and Washington State
University, our Advanced Technology Group has made important progress in
the development of QMS, IMX and DMS technologies which, when combined,
could result in high performance yet lightweight, low cost/power
technological capabilities for the detection of explosives, drugs, and
other substances.”
Mr. Thomas added, "Our expertise in the
development of miniaturized mass spectrometers and vacuum pumps,
combined with our understanding of the commercialization of devices for
explosives and drug detection should provide Implant Sciences with a
competitive advantage in the security marketplace. We are pleased the
DHS continues to support our efforts in the development of this
important technology.” About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors
and systems for the Security, Safety and Defense (SS&D) industries. The
Company has developed proprietary technologies used in its commercial
portable and bench-top explosive trace detection systems which ship to a
growing number of locations domestically and internationally. For
further details on the Company and its products, please visit the Company’s
website at www.implantsciences.com.
Safe Harbor Statement
This press release contains certain "forward-looking
statements,” as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such statements are
based on management’s current expectations
and are subject to risks and uncertainties that could cause the Company’s
actual results to differ materially from the forward-looking statements.
Such risks and uncertainties include, but are not limited to, the Company’s
ability to successfully develop the QAMS, IMS and DMS technology and
incorporate the technology into prototypes capable of detecting
explosives and narcotics; the commercialization of a prototype, if one
is developed; the market acceptance of a commercial product using the
technology; and other risks and uncertainties described in the Company’s
filings with the Securities and Exchange Commission, including its most
recent Forms 10-K, 10-Q and 8-K.
For further information, you are encouraged to review Implant Sciences’
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for the period ended June 30, 2007 and
Quarterly Reports for the periods ended September 30, 2007, December 31,
2007 and March 31, 2008. The Company assumes no obligation to update the
information contained in this press release.